AzTrials
AzTrials

Infant Pain ManagementNCT07286721

White Noise and Buzzy for Reducing Pain During Infant Vaccination

A study of Infant Pain Management, run by Istanbul Arel University at 1 site in Turkey (Türkiye).

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

This randomized controlled trial aims to evaluate the effectiveness of two non-pharmacological methods-white noise and the Buzzy device-in reducing pain experienced by infants during routine vaccination. Read more about this study

Who is it for?
Ages 2 to 6 monthsHealthy volunteers can take part
Conditions the study is for
Infant Pain Management
Could I receive a placebo?
No, everyone receives an active treatment
How many people
108 participants
Where
1 siteTurkey (Türkiye)
Study dates
25 Sep 2025to 20 May 2026
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 2 to 6 months
  • All sexes
  • Healthy volunteers accepted
  • Child

Who may be able to join

  • Infants aged 2 to 6 months
  • Receiving routine hexavalent vaccination
  • Born at term (≥37 weeks gestation)
  • Medically stable at the time of vaccination
  • Parent or legal guardian able to provide written informed consent Exclusion Criteria
  • Infants with neurological disorders or developmental delay
Show all 11Show fewer
  • Use of analgesic, antipyretic, or sedative medications within 24 hours prior to vaccination
  • Skin conditions or contraindications at the injection site
  • Hearing impairment that may affect response to white noise
  • History of adverse reactions to vaccination
  • Preterm infants (<37 weeks gestation)

Who cannot join

None listed.

Trial locations and contacts

1 site in 1 country.

Turkey (Türkiye)1 site
  • Büyükçekmece Central Family Health Center

    Istanbul, Istanbul, 34500

Other trials in Turkey (Türkiye)

About this study

Official title: The Effect of White Noise and Buzzy Use on Pain During Infant Vaccination: A Randomized Controlled Trial

This randomized controlled trial aims to evaluate the effectiveness of two non-pharmacological methods-white noise and the Buzzy device-in reducing pain experienced by infants during routine vaccination. Infants are known to feel pain, and untreated or poorly managed pain during early life may lead to negative short- and long-term outcomes. Therefore, identifying effective, safe, and easy-to-apply pain-reducing strategies is essential for improving infant comfort and supporting evidence-based nursing practices.

Read the detailed description

Pain during routine vaccination is a common clinical challenge in infancy. Although short in duration, procedural pain can cause significant distress for infants and caregivers, and repeated painful experiences during early life have been associated with negative physiological, behavioral, and neurodevelopmental outcomes. Current guidelines from pediatric and neonatal organizations emphasize the importance of minimizing pain through safe, effective, and feasible strategies. Non-pharmacological methods such as white noise and vibration-cold devices (e.g., Buzzy) are increasingly recommended because they are simple, inexpensive, and easily integrated into routine clinical workflows. However, there is limited evidence comparing the effectiveness of these two methods specifically during infant vaccination.

This study is designed as a single-center, randomized controlled, experimental trial aimed at evaluating and comparing the effects of white noise and the Buzzy device on pain experienced by infants during vaccination. The study will be conducted at the Büyükçekmece Central Family Health Center in Istanbul, Türkiye, between October 2025 and October 2026. The target population includes healthy infants aged 0 to 6 months who are scheduled to receive the routine hexavalent vaccine (diphtheria, acellular pertussis, tetanus, inactivated polio, Haemophilus influenzae type B, and hepatitis B).

A total of 108 infants will be included based on a priori power analysis performed using G*Power software, assuming an alpha level of 0.05, a power of 95%, and an anticipated large effect size. To account for potential dropout or exclusions, 36 infants will be assigned to each of the three study groups: (1) White Noise Group, (2) Buzzy Device Group, and (3) Control Group. Randomization will be conducted by an independent statistician using stratified randomization based on infant age (2, 4, or 6 months) and sex to ensure balanced distribution across groups. The study will use a single-blind design in which the observer assessing pain scores is blinded to group assignment.

In the White Noise Group, infants will listen to white noise beginning approximately 1 to 2 minutes before the vaccination and continuing throughout the procedure. The device will be placed safely within hearing distance of the infant. In the Buzzy Group, the Buzzy device-providing combined vibration and cold stimulation-will be applied approximately 3 cm above the injection site starting 60 seconds before the injection and will remain active until the end of the vaccination. In the Control Group, infants will receive the standard vaccination procedure without additional intervention. All vaccinations will be performed by the same trained nurse to ensure procedural consistency. A parent will remain present for the infant's comfort and to assist in observing behavioral cues.

Pain will be evaluated using the validated FLACC Pain Assessment Scale (Face, Legs, Activity, Cry, Consolability), a widely used behavioral tool suitable for infants and young children. During the vaccination, pain scores will be independently assessed by both a blinded observer (trained research nurse) and the parent. The total FLACC score ranges from 0 (no pain) to 10 (severe pain). Higher scores indicate greater pain. Sociodemographic data for infants and parents will also be collected using a structured introductory information form developed from relevant literature.

Data analysis will be performed using SPSS software. Normality of continuous variables will be assessed using the Kolmogorov-Smirnov test. Depending on the distribution, appropriate parametric or non-parametric tests will be applied. Between-group comparisons for FLACC scores will be conducted using ANOVA or the Kruskal-Wallis test, with post hoc analyses performed where necessary. Descriptive statistics (mean, median, standard deviation, and percentages) will be used to summarize sample characteristics. A significance level of p < 0.05 will be used for all statistical tests.

The primary objective of this study is to determine whether white noise or the Buzzy device is more effective in reducing pain during infant vaccination compared with standard care. Secondary objectives include comparing the relative effectiveness of the two methods against each other and evaluating factors that may influence pain perception, such as infant age and sex. By generating evidence on the comparative effectiveness of these widely available non-pharmacological interventions, this study aims to support the development of best practices for infant pain management in primary care settings.

The findings may inform clinical guidelines, enhance nurse-led pain management strategies, and contribute to the broader adoption of evidence-based, non-pharmacological methods in pediatric care. If shown to be effective, these techniques may be recommended for routine use during infant vaccinations to improve comfort, reduce distress, and support family-centered care. The study also seeks to raise awareness among healthcare providers and caregivers regarding simple, safe, and practical ways to reduce procedural pain in infants.

Being tested
Standard Care (in control arm)
Keywords
Infant pain, White noise, Buzzy, Vaccination, Nursing

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Standard Care (in control arm)Other

    White noise will be played 1-2 minutes before vaccination and continued throughout the procedure. The device will be placed within safe hearing distance of the infant. This auditory distraction method is intended to reduce procedural pain. No physical stimulation will be applied.

    The Buzzy device will be placed about 3 cm above the injection site 60 seconds before vaccination and kept active until the procedure ends. The device provides vibration and cold stimulation to decrease pain by activating competing sensory pathways.

    Infants in the control arm will receive routine vaccination with no additional intervention. No white noise, vibration, or cold stimulation will be used. Pain will be assessed according to standard observation procedures.

Study groups in NCT07286721
Study groupRoleWhat they receive
White Noise GroupExperimentalInfants in this group will listen to white noise beginning approximately 1-2 minutes before the vaccination and continuing throughout the injection procedure. The white noise device will be placed safely within hearing distance of the infant. Pain will be assessed using the FLACC Pain Assessment Scale by a blinded observer and a parent.
Receives: Other: Standard Care (in control arm)
Buzzy Device GroupExperimentalInfants in this group will receive vibration and cold stimulation using the Buzzy device. The device will be placed about 3 cm above the injection site 60 seconds before vaccination and will remain active until the procedure is completed. Pain will be assessed using the FLACC Pain Assessment Scale by a blinded observer and a parent.
Receives: Other: Standard Care (in control arm)
Control GroupExperimentalInfants in this group will receive routine vaccination following standard clinical practice with no additional non-pharmacological intervention. Pain will be assessed using the FLACC Pain Assessment Scale by a blinded observer and a parent.
Receives: Other: Standard Care (in control arm)

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. FLACC Pain Score During Vaccination

    Pain during vaccination will be assessed using the FLACC Pain Assessment Scale (Face, Legs, Activity, Cry, Consolability). Scores range from 0 to 10, with higher scores indicating greater pain. Pain will be independently evaluated for each infant by a blinded observer and a parent.

    Measured: Periprocedural (during vaccination)

Secondary outcomes (1)
  1. Agreement Between Parent and Observer FLACC Pain Scores

    The level of agreement between FLACC pain scores assessed by a blinded observer and a parent during infant vaccination will be evaluated. Inter-rater agreement will be analyzed to assess the reliability of observational pain assessment across the three study groups.

    Measured: Immediately after vaccination

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted16 Dec 2025
  2. Study start25 Sep 2025
  3. Primary completion1 Apr 2026
  4. Study completion20 May 2026

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Supportive care
Allocation
Randomised
Intervention model
Parallel groups
Masking
Single blind
Who is masked
Outcomes assessor
Enrolment
108 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT07286721
Sponsor's protocol ID
2025/21
Status last verified
May 2026
First submitted
3 Dec 2025
Last updated
2 Jun 2026
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No: Individual participant data will not be shared due to ethical and confidentiality considerations.

Questions about this trial

What is this clinical trial studying?

A study of Infant Pain Management, run by Istanbul Arel University at 1 site in Turkey (Türkiye).

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 11 inclusion and 0 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 2 Jun 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Turkey (Türkiye). Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

FLACC Pain Score During Vaccination (time frame: Periprocedural (during vaccination)). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 2 Jun 2026.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in